StonvexLoading…
StonvexStonvexStonvexCore line items from SSRM's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Q3 2023 2023-09-30 |
|---|---|---|---|---|
Revenue | $1.60B | $987.00M | $1.42B | $1.00B |
Operating Income | $461.44M | $-322.29M | $-130.24M | $167.38M |
Net Income | $395.75M | $-261.28M | $-98.01M | $119.84M |
EPS (Diluted) | $1.85 | $-1.29 | $-0.48 | $0.57 |
Total Assets | $6.09B | $5.19B | $5.39B | $5.75B |
Total Liabilities | $1.78B | $1.24B | $1.08B | $1.16B |
Cash & Equivalents | $524.75M | $387.88M | $492.39M | $437.68M |
Free Cash Flow OCF − CapEx | $241.65M | $-103.40M | $198.30M | $53.93M |
Shares Outstanding | 203.00M | 202.37M | 202.95M | 203.89M |